ENG
ESP
Argentine registry of COVID-19 in HIV (COVIDARE Study): clinical and epidemiological characteristics and factors associated with hospitalization
Diego Cecchini
Published 2023-06-30
Keywords
How to Cite
Copyright (c) 2023 Diego Cecchini, Fernanda Rombini, Diana Pinto, Jamile Ballivian, Liliana Calanni, Elena Obieta, Rosana Cuini, María Marta Greco, Fabricio Morales, Laura Morganti, Claudia Migazzi, Yasmin El Kozah, Pablo Parenti, Isabel Cassetti
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Background: There is controversy regarding the factors that determine a greater risk of severity and complications from COVID-19 in people living with HIV (PPHIV). Likewise, there are limited data on the impact of SARS-CoV-2 vaccination on hospitalization in this population. Aims:
- To describe clinical characteristics and outcome of COVID-19 in PLHIV
- To assess risk factors for hospitalization
- To evaluate the impact of vaccination on hospitalization.
Methods: Multicenter, prospective, observational study (September 2020 to June 2022). Clinical and immunovirological variables, antiretroviral treatment (ART), SARS-CoV-2 vaccination, and hospitalization in PLHIV with COVID-19 were recorded. Univariate and multivariate analyzes were performed examining factors associated with hospitalization using two models: first model (without vaccination) and second model (vaccination, minimum one dose). Results: 1201 PLHIV were included. The median age was 45 years. 65.3% were men; 38.7% presented comorbidities. 92.8% received ART and 83.1% presented undetectable viral load (VL). The median CD4+ T-cell count was 600/mm3. 95.7% presented symptoms. The rates of hospitalization, ICU admission, oxygen requirement, and death were 17,8 %, 2,8%, 10,7% and 1,39%, respectively. According to the multivariate analysis for the first model, age >60 years and comorbidities were associated with a higher risk of hospitalization, while female sex and CD4+ >500/mm3 had a protective effect. In the second model, only the comorbidities were associated with a higher risk of hospitalization, while vaccination and CD4+ >500/mm3 reduced it. Conclusions: in PLHIV, comorbidities were associated with a higher hospitalization rate, while having elevated CD4+ T-cell counts and being vaccinated had a protective effect. ART and VL had no impact in any model, while age and sex only had an influence when vaccination was not considered.